Natus Medical Incorporated, commonly referred to as Natus, is a leading provider of medical devices and services headquartered in the United States. Founded in 1989, the company has established a strong presence in the neurodiagnostic, newborn care, and hearing screening sectors, serving healthcare professionals across North America and globally. Natus is renowned for its innovative products, including advanced neurodiagnostic systems, neonatal monitoring solutions, and audiology equipment, which are designed to enhance patient care and improve clinical outcomes. The company’s commitment to quality and technological advancement has positioned it as a trusted partner in the medical community. With a focus on delivering exceptional value, Natus has achieved significant milestones, including numerous industry awards and recognitions, solidifying its status as a key player in the medical technology landscape.
How does Natus Medical Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Natus Medical Incorporated's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Natus Medical Incorporated reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 and 282,600 kg CO2e from Scope 2. This data reflects the company's operational emissions and energy-related emissions, with no reported Scope 3 emissions. Comparatively, in 2021, the company had significantly higher emissions, with Scope 1 alone accounting for about 533,000,000 kg CO2e. This indicates a substantial reduction in emissions from 2021 to 2022, although specific reduction targets or initiatives have not been disclosed. Natus Medical has not established any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges, indicating a potential area for future commitment. The absence of cascaded emissions data suggests that the company is independently reporting its emissions without influence from a parent organisation. Overall, while Natus Medical has made progress in reducing its carbon footprint, further transparency regarding its climate commitments and future reduction strategies would enhance its sustainability profile.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Natus Medical Incorporated has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
